Developing ultra-low cost seawater desalination and water treatment

WATERTOWN, Mass.--(BUSINESS WIRE)--Selecta Biosciences, Inc., a privately held biopharmaceutical company developing immunomodulatory nanoparticles for the treatment and prevention of human diseases, announced today that it has secured a $15.1M Series B financing. Existing investors, Polaris Venture Partners and Flagship Ventures were joined by NanoDimension and Professor Timothy A. Springer. “I am pleased by the strength of our investors whose track record of creating successful companies is a loud validation of our team, technology platform, and product opportunities” said Dr.

SAN FRANCISCO, Calif., CAMBRIDGE, Mass. and Gaithersburg, Md., February 25, 2009 – (CHI’s Molecular Medicine Tri-Conference) - Genstruct Inc., a systems biology company focused on identifying molecular mechanisms, networks and biomarkers to better develop novel therapeutics, molecular diagnostics and patient-specific therapies, today announced that it has signed a partnership agreement with Gene Logic, an Ocimum Biosolutions company, for a systems toxicology collaboration.

Facility Generating Biomass-based Ethanol With Assistance from New York State Agencies

Boston, MA – February 25, 2009: Mascoma Corporation, a leader in the development of low carbon cellulosic ethanol, today announced that the company’s demonstration facility in Rome, New York, is now producing ethanol from non-food cellulosic biomass.

Waltham, Mass. – BG Medicine Inc. (BGM) today announced that Doug White has joined the organization as Executive Vice President & General Manager, Diagnostics. In this newly created role, Mr. White will be responsible for the strategic direction and overall management of the company’s commercial operations as it advances a broad portfolio of high-value diagnostic tests toward commercial launch.

Market Vision, Engineering Know-how, and Smart Plastics Expertise Combine to bring Practical Cell Technologies to the Life Sciences

N. Billerica, MA – March 9, 2009 - Seahorse Bioscience, Inc., manufacturer of instruments and consumables for cell based metabolic assays today announced the acquisition of BioProcessors Corp., manufacturer of systems for optimizing biologic drug manufacturing. The two companies will be integrated and operate under the Seahorse name.

Biosamples from the Framingham Heart Study will be used to Discover New Blood Tests for Heart Disease

WALTHAM, Mass., March 12 /PRNewswire/ -- BG Medicine, a biotechnology company focused on the discovery and development of novel diagnostic biomarkers, today announced the signing of a Cooperative Research and Development Agreement (CRADA) with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health and Boston University (BU).

First Clinical Demonstration of Concert’s Technology Platform

WALTHAM, Mass. – (BUSINESS WIRE) - BG Medicine Inc. (BGM), a developer of novel,biomarker-based diagnostic products, today announced the launch of the Galectin-3 Website (www.galectin-3.com) which will provide an array of research materials associated with galectin-3.

Alliance will deploy EnsemblinTM platform to access new therapeutic opportunities

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ensemble Discovery today announced the initiation of a strategic alliance with Bristol-Myers Squibb Company (NYSE: BMY) to discover and develop drug candidates of a novel class against a number of high-value pharmaceutical targets.